Last reviewed · How we verify
NCT06747234
Oat Bran and Plasma Lipid and Fecal Bacteria in Coronary Artery Disease Patients
NA trial testing Oat bran group in Coronary Arterial Disease (CAD) in 32 participants. Completed in 24 December 2025.
18 December 2025
Quick facts
| Lead sponsor | Shahid Beheshti University of Medical Sciences |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 32 |
| Start date | 20 May 2025 |
| Primary completion | 18 December 2025 |
| Estimated completion | 24 December 2025 |
| Sites | 2 locations across Iran |
Drugs / interventions tested
- Oat bran group
- Control (Standard treatment) — full drug profile →
Conditions studied
- Coronary Arterial Disease (CAD) — all drugs for Coronary Arterial Disease (CAD) →
Sponsor
Shahid Beheshti University of Medical Sciences
Who can join
Adults 40 to 75, any sex, with Coronary Arterial Disease (CAD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The development of atherosclerosis is significantly influenced by the interplay between lipid and inflammatory factors. Endotoxemia, defined as the presence of endotoxins, particularly lipopolysaccharides (LPS) derived from Gram-negative bacteria, in the bloodstream, is closely associated with low-grade inflammation. This chronic, systemic inflammatory response does not reach the severity of acute inflammation but can contribute to the development of atherosclerosis and cardiovascular disease (CVD). Lipopolysaccharide-binding protein (LBP) is a soluble acute-phase protein that binds to bacterial LPS. Elevated levels of LBP have been linked to increased low-grade inflammation, which further exacerbates chronic inflammation and metabolic dysregulation. Dietary fiber, such as oat bran, may have a role in mitigating the effects of endotoxemia and its associated inflammation. Furthermore, dietary fiber could play a role in improving plasma lipid profiles. The present study will investigate the effect of oat bran supplementation on cardiometabolic risk markers, LBP concentrations, selected fecal bacteria, and short-chain fatty acids receptors gene expression in peripheral blood mononuclear cells in patients with coronary artery disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06747234
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Coronary Arterial Disease (CAD)
Currently open trials in the same condition.
- NCT07444957 — Safety and Effectiveness of the Crystalline Sirolimus-Eluting Device in Patients With Coronary Artery Disease · recruiting
- NCT06855537 — Effectiveness of Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques · Phase 4 · recruiting
- NCT07025148 — Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding · Phase 4 · recruiting
- NCT07093788 — Super High-pressure Balloon Versus Intravascular Lithotripsy to Prepare Severely Calcified Coronary Lesions · NA · recruiting
- NCT07041359 — Pre-trial of Clinical Trial of Traditional Chinese Medicine Treatment for Elderly Patients With Coronary Heart Disease W · Phase 4 · recruiting
Other Shahid Beheshti University of Medical Sciences trials
Trials by the same sponsor.
- NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
- NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
- NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
- NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
- NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06747234 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
- Last refreshed: 24 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06747234.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing